Ottawa, ON / Accesswire / Mar 17 2014
/ - Avivagen Inc. (TSXV:VIV), a wellness company developing
and delivering products that support and enhance the health and
quality of life of animals and the people who care for them,
announces the release and website posting of a CEO update letter.
In addition to reading the contents of the CEO update letter below,
we encourage you to visit the Avivagen website to learn more about
the company, at www.avivagen.com.
Dear Shareholders,
It is my pleasure to provide a further update on the progress of
our Company - after one year as CEO.
The key aspects of my previous two updates remain very much in
place - that we have a great team, an exciting technology and
substantial market opportunities. With those assets, we are making
progress towards achieving many corporate goals and building
sustained value for our shareholders. This 12 month milestone
provides a good time to reflect upon and update you about our
progress.
Generally, this past year was defined by glory-free positioning
work: Getting our team to the part of the rink where we can take
shots on goal and score. But unlike hockey, moving the corporate
puck up the ice is not a visible process and management expects no
cheers for the task - it's what you pay us to do.
Comparing today with a year ago is revealing: Today, the Company
has a stronger balance sheet and has developed three discrete
product distribution and marketing channels. We have built multiple
customer and distributor relationships intended to enable us to
access Asian livestock markets. We also have fostered two market
channels for our companion animal products in the United States -
directly to consumers on our own and to veterinarians via a major
multinational. For the balance of 2014, management's task will be
to build on those foundations with the goal of generating an
increasing stream of sustained revenues from those potential
sources.
Candidly, we have greater confidence where matters are directly
under our control and supervision. We are therefore most confident
of our success in the international livestock markets - where
business development and sales support is led by our executives and
close associates. In turn, we believe our highest risk areas to be
where we are more reliant on third parties.
As your CEO and a fellow shareholder, I am very optimistic about
the balance of 2014. During the rest of this year I hope and expect
we will formalize a series of clinical trial and customer
relationships. This should include Avivagen-sponsored livestock
trials intended to result in approvable product claims and
customer-sponsored livestock trials that result in sales. We are
also working to develop the sales of our Vivamune and Oximunol
companion animal product lines. We will report progress as it is
achieved and we foresee a relatively full calendar of milestone
disclosures.
Finally, it is not sound business practice to build a company on
a single technology - no matter how promising. OxC-beta is no
exception to this maxim. Accordingly, we are evaluating veterinary
products and technologies that Avivagen can in-license on
acceptable terms and that we believe will add shareholder value.
Your management hopes to secure at least one such licensing
opportunity over the remainder of 2014.
Near and long term, we remain committed to making Avivagen into
a pre-eminent creator of products for companion and food animals.
We believe that goal can be realised using internal skills for
validating product applications, creating marketable product
formulations and managing other key commercialization tasks. Your
management believes this model is capable of building exceptional
value for our shareholders.
I look forward to providing further updates and thank you for
being a shareholder of Avivagen, for taking the time to read this
update and for your continuing support for our efforts.
Sincerely,
Cameron Groome
CEO & President
Avivagen Inc.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading
on the TSX Venture Exchange under the ticker symbol "VIV". The
Company's goal is to develop and deliver scientifically-proven
solutions that can truly benefit companion and production animals
by employing natural mechanisms for maintaining good health.
Avivagen's targeted markets include Livestock Productivity and Pet
Wellness.
The company has sites located in partnership facilities of the
National Research Council of Canada (NRC) - in Ottawa, Ontario and
Charlottetown, Prince Edward Island. More information can be found
at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology is based
on its discoveries concerning carotenoid antioxidants. The novel
natural compounds discovered by Avivagen support the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's commercial-stage application of its
technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta
compounds occur naturally as carotenoid oxidation products in
vegetation, but in minute amounts. They have been developed to
support the health of companion animals and for use in the global
food animal market.
Research and study results indicate OxC-beta supports innate
immune function, which can help maintain good health. In pets,
OxC-beta supports overall vitality and energy, mobility and joint
function, skin, coat and gut. Results observed in food animals have
included healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are OxC-beta for livestock,
Vivamune(TM) Health Chews and Oximunol(TM) Chewables.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0
or 5.0 Kg quantities for parts-per-million addition to animal
feeds, in accordance with producer-developed protocols. In past
studies, OxC-beta has been shown to support health and growth in
species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
About Vivamune(TM) Health Chews - For
dogs and cats
Vivamune(TM) Health Chews, containing Avivagen's
proprietary active ingredients, are scientifically-formulated chews
for dogs and cats. Vivamune(TM) Health Chews work with a pet's own
immune system to maintain overall health and well-being. They are
sold in re-sealable packages of 30 chews and are currently
available in the United States by ordering on-line at
www.vivamunehealth.com.
About Oximunol(TM) Chewables - For
dogs
Oximunol(TM) Chewables are scientifically-formulated chewable
tablets that contain Avivagen's proprietary, patented active
ingredient OxC-beta. OxC-beta has been shown to stimulate innate
cellular immunity and may thereby help to maintain overall health
and well-being. Oximunol(TM) Chewables are distributed by Bayer
Healthcare LLC and are available through veterinarians for dogs of
all ages in the United States.
Forward Looking
Statements
This document includes certain
forward-looking statements that are based upon current
expectations, which involve risks and uncertainties associated with
the business of Avivagen Inc. and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions "will", "anticipate",
"believe", "plan", "estimate", "expect", "intend", and similar
expressions. Statements relating to expectations regarding access
to new markets, new or increased revenue streams, Avivagen's
ability to secure additional clinical trials and customer
relationships and the results of such trials and relationships and
Avivagen's intention to identify suitable technology license
opportunities are all examples of forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ
materially from current expectations. Avivagen's products may not
gain market acceptance in new markets, new or expected revenue
streams may not materialise in the near term or at all, Avivagen
may not be able to secure clinical trials or new customer
relationships and the results of such trials and relationships may
not be favourable and Avivagen may not be able to identify suitable
in-bound technologies to license and/or It may fail to negotiate a
license on terms acceptable to Avivagen. Unless required by law,
Avivagen Inc. assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those reflected in the forward-looking statements.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
c.groome@avivagen.com
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com
-----------------
|Copyright© 2014|
|Avivagen |
-----------------
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Avivagen (TSXV:VIV)
Historical Stock Chart
From Feb 2024 to Feb 2025
